1 min read
ASH Annual Meeting and Exposition
Meet Veristat at ASH Meeting and Exposition December 6-9, 2025
Veristat is excited to attend the ASH Annual Meeting and...
1 min read
Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology sponsor to advance dose escalation strategies through Bayesian modeling in a Phase 1/2 study for a novel oncology compound. Our efforts led to real-time, data-driven decision making and reduced trial duration while maintaining patient safety.
A biotechnology sponsor developing an oncology therapy engaged us to support the design and execution of a multicenter, open-label Phase 1/2 dose escalation and expansion study. The sponsor aimed to shorten traditional dose escalation timelines without compromising patient safety, moving beyond conventional 3+3 design limitations.
In this case study, learn how Veristat experts were able to work with the sponsor to solve challenges across:
-
Bayesian CRM implementation
-
Real-time decision support
-
Operational complexity management
-
Safety review committee participation
-
Multi-cycle DLT integration
-
Strategic consultative planning
Download our complete case study "Advancing Dose Escalation Strategies with Bayesian Modeling"
